Nxera Pharma swings to FY26 H1 net profit of JPY 1.59 billion; revenue rises to JPY 18.91 billion
Reuters2026/08/07 06:30- Nxera Pharma posted revenue of JPY 18.91 billion for the six months ended June 30, up JPY 3.82 billion from the prior corresponding period.
- Operating profit turned to JPY 1.88 billion from an operating loss of JPY 2.76 billion; net profit swung to JPY 1.59 billion from a net loss of JPY 3.14 billion.
- R&D expenses fell JPY 1.47 billion to JPY 6 billion on maturation of several clinical programs; SG&A decreased JPY 612 million to JPY 6.95 billion on cost cuts.
- Cash and cash equivalents slipped JPY 2.62 billion from fiscal year-end to JPY 17.75 billion.
- First-half updates included rising Japan sales of PIVLAZ and QUVIVIQ, South Korea fast-track designations for vamorolone, and milestone payments from AbbVie, Lilly, Neurocrine and the Centessa collaboration.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Crude oil is "coming back", but refined oil is "not coming back"; the global refining gap is widening.
According to Goldman Sachs, global refined oil exports have declined by about 6 million barrels per day year-on-year, with the Gulf region and Russia contributing three-quarters of the decrease. Unlike crude oil, which can be rerouted, damaged refineries cannot be relocated, and the Gulf region's refined oil exports have only recovered to 40% of pre-war levels. Goldman Sachs expects global refinery utilization rates to recover only by the second half of 2027; based on this, it has more than doubled its forecast for diesel profit margins in 2027.
Data: Detected an outflow of 35.11 million USDT from a certain exchange
SK Hynix CEO: Memory chip shortage will persist until 2030
Crypto prices
More
